Factors influencing the economics of biosimilars in the US

J Med Econ. 2017 Dec;20(12):1268-1271. doi: 10.1080/13696998.2017.1366325. Epub 2017 Aug 29.

Authors

Stanton R Mehr^{1

2}, Richard A Brook^{3

4

5}

Affiliations

¹ a SM Health Communications , Newtown , PA , USA.
² b Biosimilars Review and Report , Newtown , PA , USA.
³ c Retrospective Analysis , Newfoundland , NJ , USA.
⁴ d The JeSTARx Group , Newfoundland , NJ , USA.
⁵ e Better Health Worldwide , Newfoundland , NJ , USA.

PMID: 28796564
DOI: 10.1080/13696998.2017.1366325

No abstract available

MeSH terms

Biosimilar Pharmaceuticals / economics*
Biosimilar Pharmaceuticals / standards*
Costs and Cost Analysis / methods
Humans
Insurance, Health, Reimbursement
United States
United States Food and Drug Administration / standards

Substances

Biosimilar Pharmaceuticals